Electromed, Inc. (ELMD)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
$26.77-4.43%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · ELMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth.
Stated in 2 of 2 supplied quarters. Management reported: “The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth.” “Net revenues for fiscal 2026 grew by 15.3% to a record $ 73.8 million, from $ 64.0 million in fiscal 2025.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth.”
““I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth.”
Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage.
Stated in 2 of 2 supplied quarters. Management reported: “Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage.” “Operating income was $ 13.9 million or 18.8% of net revenues in fiscal 2026, compared to $ 9.7 million, or 15.1% of net revenues in fiscal 2025.”
“Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage.”
“● Operating income increased to a record $ 3.8 million, a 76.0% increase from the third quarter of the prior fiscal year, and 20.3% of net revenues.”
Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to…
Stated in 2 of 2 supplied quarters. Management reported: “Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to serve the approximately 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest® therapy.” “With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis market.”
“Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to…”
“With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis marke…”
Over the trailing year it converted 0.67x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.